-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head to Head Contrast: Fresh Tracks Therapeutics (FRTX) and Its Rivals
Head to Head Contrast: Fresh Tracks Therapeutics (FRTX) and Its Rivals
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 276 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its rivals? We will compare Fresh Tracks Therapeutics to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Volatility and Risk
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Get Fresh Tracks Therapeutics alerts:Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.07% | -37.03% |
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.7% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all "Biological products, except diagnostic" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 873 | 3827 | 10681 | 159 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 133.90%. As a group, "Biological products, except diagnostic" companies have a potential upside of 81.42%. Given Fresh Tracks Therapeutics' higher possible upside, equities research analysts plainly believe Fresh Tracks Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Fresh Tracks Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.20 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -1.75 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 7 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 276 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its rivals? We will compare Fresh Tracks Therapeutics to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Fresh Track Treateutics(纳斯达克代码：FRTX-GET Rating)是除诊断外的生物制品行业的276家上市公司之一，但它与竞争对手有何不同？我们将根据机构所有权、股息、收益、分析师建议、盈利能力、风险和估值将Fresh Track Treateutics与相关公司进行比较。
Volatility and Risk
波动性和风险
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Fresh Track治疗公司的贝塔系数为0.29，这表明其股价的波动性比标准普尔500指数低71%。相比之下，Fresh Track Treeutics的竞争对手的贝塔系数为0.75，这表明它们的平均股价波动性比标准普尔500指数低25%。
Profitability
盈利能力
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
下表比较了Fresh Track治疗公司及其竞争对手的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.07% | -37.03% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 新奇轨道治疗公司 | -453.11% | -133.55% | -108.52% |
| Fresh Track Treateutics竞争对手 | -4,576.34% | -104.07% | -37.03% |
Insider and Institutional Ownership
内部人与机构持股
Analyst Ratings
分析师评级
This is a summary of recent ratings and recommmendations for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.
据MarketBeat.com报道，这是对Fresh Track治疗公司及其竞争对手最近的评级和推荐的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 873 | 3827 | 10681 | 159 | 2.65 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 新奇轨道治疗公司 | 0 | 0 | 0 | 0 | 不适用 |
| Fresh Track Treateutics竞争对手 | 873 | 3827 | 10681 | 159 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 133.90%. As a group, "Biological products, except diagnostic" companies have a potential upside of 81.42%. Given Fresh Tracks Therapeutics' higher possible upside, equities research analysts plainly believe Fresh Tracks Therapeutics is more favorable than its rivals.
Fresh Track治疗公司目前的共识目标价为4.00美元，暗示潜在上涨133.90%。作为一个整体，“生物制品，除诊断”公司有81.42%的潜在上行空间。考虑到Fresh Track治疗公司更高的可能上行空间，股票研究分析师显然认为Fresh Track治疗公司比其竞争对手更有利。
Valuation and Earnings
估值和收益
This table compares Fresh Tracks Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
此表比较了Fresh Track Treeutics及其竞争对手的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.20 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -1.75 |
| 总收入 | 净收入 | 市盈率 | |
| 新奇轨道治疗公司 | $400,000.00 | -3,947万元 | -0.20 |
| Fresh Track Treateutics竞争对手 | 7.6719亿美元 | 1.4684亿美元 | -1.75 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Fresh Track治疗公司的竞争对手比Fresh Track治疗公司有更高的收入和收益。Fresh Track治疗公司的市盈率高于竞争对手，这表明它目前的价格高于行业内的其他公司。
Summary
摘要
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 7 of the 10 factors compared.
Fresh Track治疗公司的竞争对手在比较的10个因素中有7个击败了Fresh Track治疗公司。
About Fresh Tracks Therapeutics
关于Fresh Track治疗公司
(Get Rating)
(获取评级)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Track治疗公司是一家临床阶段的制药公司，致力于开发各种处方疗法，用于治疗美国的自身免疫、炎症和其他令人衰弱的疾病。该公司开发的产品包括：已完成治疗原发性腋窝多汗症的第三阶段临床试验的索吡溴铵；用于治疗自身免疫和炎症性疾病的口服DYRK1A抑制剂BBI-02；以及用于潜在治疗自体炎症和罕见遗传性疾病的干扰素基因共价刺激物BBI-10，以及下一代激酶抑制剂。它与Carna Biosciences，Inc.，Voronoi Inc.，Bodor实验室，Inc.和Nicholas S.Bodor博士以及Anges，Inc.签订了许可和合作协议。该公司前身为Brickell Biotech，Inc.，并于2022年9月更名为Fresh Track治疗公司。Fresh Track治疗公司成立于2009年，总部设在科罗拉多州博尔德市。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受新闻和评级的新轨道治疗每日-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Fresh Track Treeutics和相关公司的评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧